Lexeo Advances LX2006 Pivotal Program; SUNRISE-FA 2 Data Expected In 2H27
(RTTNews) - Lexeo Therapeutics, Inc. (LXEO), a clinical-stage genetic medicine company focused on developing treatments for cardiovascular diseases, has reported its second-quarter 2026 financial results and provided business updates, highlighting the initiation of the pivotal SUNRISE-FA 2 trial for LX2006 and regulatory progress for LX2020.
Recent Business & Clinical Updates:
Lexeo finalized the SUNRISE-FA 2 pivotal trial protocol and statistical analysis plan (SAP) for LX2006 under the accelerated approval pathway.
The company initiated SUNRISE-FA 2 in June 2026, with the first trial site activated and the first patient enrolled. Additional site activation efforts are ongoing to support continued enrollment.
Enrollment in the CLARITY-FA natural history study continues across multiple U.S. and international sites, with eligible participants able to enroll in SUNRISE-FA 2.
Lexeo reported that previously generated LX2006 data published in JAMA Cardiology demonstrated that the therapy was generally well tolerated, with signs of efficacy in Phase 1/2 studies.
For LX2020 in PKP2 arrhythmogenic cardiomyopathy, the FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation based on recent interim clinical data.
LX2020 remains generally well tolerated across 10 participants, with no clinically significant complement activation reported to date.
Lexeo also presented preclinical data for LX2022, demonstrating proof-of-concept efficacy for TNNI3 gene replacement in a porcine model of hypertrophic cardiomyopathy.
Q2 2026 Performance:
Lexeo reported R&D expenses of $19.0 million, compared with $14.7 million in Q2 2025.
General and administrative expenses declined to $9.0 million, compared with $16.0 million in the prior-year quarter.
The company reported a net loss of $25.9 million, or $0.30 per share, compared with a net loss of $26.1 million, or $0.60 per share, in Q2 2025.
The Road Ahead:
The key near-term catalyst for LX2006 is continued enrollment and execution of the SUNRISE-FA 2 pivotal trial, with topline data expected in the second half of 2027.
Lexeo expects continued FDA engagement regarding the confirmatory evidence strategy and is targeting a potential BLA submission in the first half of 2028 under the accelerated approval pathway.
For LX2020, a 12-month data update for all high-dose participants is expected in Q4 2026, alongside further regulatory engagement with the FDA.
LX2006 & LX2020 Programs:
LX2006 is being developed as a potential disease-modifying gene therapy for Friedreich ataxia cardiomyopathy, while LX2020 is being evaluated as a genetic medicine for PKP2 arrhythmogenic cardiomyopathy.
The programs are part of Lexeo's broader strategy of developing genetic medicines targeting the underlying causes of genetically defined cardiovascular diseases.
Cash Position:
Lexeo held $234.2 million in cash, cash equivalents and investments in marketable securities as of June 30, 2026.
The company expects its current financial resources to support operations into 2028, providing funding for key clinical and regulatory milestones across its pipeline.
LXEO closed Tuesday's trading at $4.78, up 3.24%. In premarket trading today, the stock is down 1.05% at $4.83.
